Table 1.
Cost benefit and cost-effectiveness analysis of infant hepatitis B vaccine and PMTCT, compared to no intervention
| Strategy | Cost (USD) | QALYs | Benefit | NB | BCR | ||
|---|---|---|---|---|---|---|---|
| Immunization | Infection | Total | |||||
| Status quo | |||||||
| Infant hepatitis B vaccine | 52.17 | 1208.61 | 1260.78 | 23.88 | 11,968.42 | 11,916.25 | 9.49 |
| PMTCT | 76.37 | 893.52 | 969.89 | 23.92 | 12,283.50 | 12,207.14 | 12.66 |
| Comparison scenario | |||||||
| Without any interventions | 0 | 13,177.03 | 13,177.03 | 22.34 | – | – | – |
Note: All costs were adjusted with respect to the cost of dollar according to the exchange rate in 2018
USD US dollar, QALY quality-adjusted life year, NB net benefit, BCR benefit–cost ratio, PMTCT the prevention of mother-to-children transmission